Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Moreover, in a model of hyperoxia-induced ALI, exosomes derived from MSCs ameliorated the decrease in PI3K and AKT phosphorylation caused by oxidative damage in rat lung tissue by activating the ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend ... but Roche is confident in the drug’s best-in-class potential, head of oncology and hematology global product development ...

"It's especially exciting to integrate world-class AI capabilities with groundbreaking ... Dr. Lew Cantley (Harvard University), discoverer of PI3K and PTEN, scientific founder of Agios Pharma ...